Primary carnitine deficiency in the chinese

Chinese Medical Journal

Volumn 113, Issue 4, 2000, Pages 376-380

  Tang, Nelson Leung Sang ^a   Hui, Joannie ^a   Law, Lap Kay ^a   To, Ka Fai ^a   Cheung, Kam Lau ^a   Hjelm, N Magnus ^a   Yuen, Patrick Man Pan ^a   Fok, Tai Fai ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; CARRIER PROTEIN; MEMBRANE PROTEIN; ORGANIC CATION TRANSPORTER; SLC22A5 PROTEIN, HUMAN;

GENETICS; HUMAN; MUTATION; REVIEW;

CARNITINE; CARRIER PROTEINS; HUMANS; MEMBRANE PROTEINS; MUTATION; ORGANIC CATION TRANSPORT PROTEINS;

EID: 0034174923     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Karpati G, Carpenter S, Engel AG, et al. The syndrome of systemic carnitine deficiency: clinical, morphologic, biochemical, and pathophysiologic features. Neurology 1975;25:16-24.
2. Cruse RP, Di Mauro S, Towfighi J, et al. Familial systemic carnitine deficiency. Arch Neurol 1984;41:301-305.
3. Chapoy PR, Angelini C, Brown WJ, et al. Systemic carnitine deficiency: a treatable inherited lipid-storage disease presenting as Reye's syndrome. N Engl J Med 1980;303:1389-1394.
4. Tang NL, Hui J, Law LK, et al. Primary plasmalemmal carnitine transporter defect manifested with dicarboxylic aciduria and impaired fatty acid oxidation. J Inherit Metab Dis 1998;21:423-425.
5. Boles RG, Buck EA, Blitzer MG, et al. Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. J Pediatr 1998;132:924-933.
6. Bremer J. The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 1990;28:297-301.
7. Pons R, de Vivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995;10(Suppl 2):S8-S24.
8. Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis. New Engl J Med 1981;305:385-390.
9. Stanley CA, DeLeeuw S, Coates PM, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991;30:709-716.
10. Matsuishi T, Hirata K, Terasawa K, et al. Successful carnitine treatment in two siblings having lipid storage myopathy with hypertrophic cardiomyopathy. Neuropediatr 1985;16:6-12.
11. Garavaglia B, Uziel G, Dworzak F, et al. Primary carnitine deficiency: heterozygote and intrafamilial phenotypic variation. Neurology 1991;41:1691-1693.
12. Stadler DD, Bale JF Jr, Chenard CA, et al. Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans. Metabolism 1999;48:74-79.
13. Castro-Gago M, Eiris-Punal J, Novo-Rodriguez MI, et al. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol 1998;13:546-549.
14. de Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998;39:1216-1225.
15. Melegh B, Pap M, Molnar D, et al. Carnitine administration ameliorates the changes in energy metabolism caused by short-term pivampicillin medication. Eur J Pediatr 1997;156:795-799.
16. Abrahamsson K, Eriksson BO, Holme E, et al. Pivalic acid-induced carnitine deficiency and physical exercise in humans. Metabolism 1996;45:1501-1507.
17. Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989;2: 469-473.
18. Tein I, DiMauro S, Xie ZW, et al. Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. J Inherit Metab Dis 1995;18:313-322.
19. Duran M, Loof NE, Ketting D, et al. Secondary carnitine deficiency. J Clin Chem Clin Biochem 1990;28:359-363.
20. Treem WR, Stanley CA, Finegold DN, et al. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 1988;319:1331-1336.
21. Tein I, Xie ZW. The human plasmalemmal carnitine transporter defect is expressed in cultured lymphoblasts: a new non-invasive method for diagnosis. Clin Chim Acta 1996;252:201-204.
22. Christodoulou J, Teo SH, Hammond J, et al. First prenatal diagnosis of the carnitine transporter defect. Am J Med Genet 1996; 66:21-24.
23. Marques JS. Dilated cardiomyopathy caused by plasma membrane carnitine transport defect. J Inherit Metab Dis 1998;21:428-429.
24. Rebouche CJ. Carnitine function and requirements during the life cycle. Faseb J 1992;6:3379-3386.
25. Fraenkel G, Friedmann S. Carnitine. Vitam Horm 1957;15: 73-118.
26. Rebouche CJ, Engel AG. Primary systemic carnitine deficiency: I . Carnitine biosynthesis. Neurology 1981;31:813-818.
27. Stanley CA. Carnitine disorders. Adv Pediatr 1995;42:209-242.
28. Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr 1998;18: 39-61.
29. Engel AG, Rebouche CJ, Wilson DM, et al. Primary systemic carnitine deficiency. II . Renal handling of carnitine. Neurology 1981;31:819-825.
30. Prasad PD, Huang W, Ramamoorthy S, et al. Sodium-dependent carnitine transport in human placental choriocarcinoma cells. Biochim Biophys Acta 1996;1284:109-117.
31. Roque AS, Prasad PD, Bhatia JS, et al. Sodium-dependent high-affinity binding of carnitine to human placental brush border membranes. Biochim Biophys Acta 1996;1282:274-282.
32. Nikaido H, Horiuchi M, Hashimoto N, et al. Mapping of jvs (juvenile visceral steatosis) gene, which causes systemic carnitine deficiency in mice, on chromosome 11. Mamm Genome 1995;6:369-370.
33. Shoji Y, Koizumi A, Kayo T, et al. Evidence for linkage of human primary systemic carnitine deficiency with D5S436: a novel gene locus on chromosome 5q. Am J Hum Genet 1998;63:101-108.
34. Wu X, Prasad PD, Leibach FH, et al. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 1998;246:589-595.
35. Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998;273:20378-20382.
36. Wang Y, Ye J, Ganapathy V, et al. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci U S A 1999;96:2356-2360.
37. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999;21:91-94.
38. Tang NL, Ganapathy V, Wu X, et al. Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency. Hum Mol Genet 1999; 8:655-660.
39. Lu K, Nishimori H, Nakamura Y, et al. A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. Biochem Biophys Res Commun 1998;252:590-594.
40. Zhang L, Brett CM, Giacomini KM, et al. Role of organic cation transporters in drug absorption and elimination. Organic cation transporters in intestine, kidney, liver, and brain. Ann Rev Pharmacol Toxicol 1998;38:431-460.
41. Koepsell H. Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 1998;60:243-266.
42. Tamai I, Yabuuchi H, Nezu J, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. Febs Lett 1997;419:107-111.
43. Lamhonwah AM, Tein I. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transporter gene. Biochem Biophys Res Commun 1998;252:396-401.